Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.87 USD
Change Today -0.0899 / -1.29%
Volume 1.3K
ICCC On Other Exchanges
Symbol
Exchange
Berlin
As of 12:28 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

immucell corp (ICCC) Snapshot

Open
$6.96
Previous Close
$6.96
Day High
$6.96
Day Low
$6.50
52 Week High
02/12/15 - $7.22
52 Week Low
05/14/14 - $3.30
Market Cap
20.8M
Average Volume 10 Days
2.8K
EPS TTM
$-0.06
Shares Outstanding
3.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUCELL CORP (ICCC)

Related News

No related news articles were found.

immucell corp (ICCC) Related Businessweek News

No Related Businessweek News Found

immucell corp (ICCC) Details

ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity in the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for newborn calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that is used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent calf scours caused by enteric pathogens in addition to E. coli K99 and bovine coronavirus. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.

immucell corp (ICCC) Top Compensated Officers

Chief Executive Officer, President, Chief Fin...
Total Annual Compensation: $240.0K
Chief Scientific Officer, Vice President and ...
Total Annual Compensation: $140.0K
Vice President of Sales and Marketing
Total Annual Compensation: $164.4K
Compensation as of Fiscal Year 2013.

immucell corp (ICCC) Key Developments

ImmuCell Corporation Reports Results From Rotavirus Pivotal Effectiveness Study

ImmuCell Corporation announced positive results from its pivotal study to prevent scours (diarrhea) in newborn calves caused by rotavirus. The pivotal effectiveness study, designed to evaluate the company's First Defense milk (colostrum) protein purification technology against a rotavirus challenge, was initiated at Cornell University College of Veterinary Medicine during the second quarter of 2014. The underlying rotavirus vaccine technology, used to generate the specific antibodies, has been licensed exclusively to the Company from Baylor College of Medicine. This product is subject to review and approval by the USDA before any sales can be made.

Boldimmucell Corporation Appoints Bobbi Jo Brockmann as Vice President of Sales and Marketing

boldImmuCell Corporation announced that Bobbi Jo Brockmann (Kunde) has been promoted to Vice President of Sales and Marketing. Ms. Brockmann joined ImmuCell as Director of Sales and Marketing in 2010. She has been in charge of the sales and marketing of boldFirst Defense® and related product line extensions. She has an network and a experience in the field of newborn calf health.

ImmuCell Corporation Announces Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

ImmuCell Corporation announced unaudited earnings results for the fourth quarter and year ended December 31, 2014. For the fourth quarter ended December 31, 2014, product sales increased by 41% to $2,205,000 compared to $1,559,000 during the same period of the prior year. Net operating income was $199,000 compared to net operating loss of $210,000 a year ago. Income before income taxes was $189,000 compared to loss before income taxes of $253,000 a year ago. Net income was $131,000 or $0.14 per diluted share compared to net loss of $151,000 or $0.05 per diluted share a year ago. For the year ended December 31, 2014, product sales increased by 26% to $7,597,000 compared to $6,007,000 in the prior year. Net operating loss was $206,000 compared to $20,000 a year ago. Loss before income taxes was $255,000 compared to income before income taxes of $205,000 a year ago. Net loss was $167,000 or $0.06 per diluted share compared to net income of $117,000 or $0.04 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICCC:US $6.87 USD -0.0899

ICCC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Novartis AG SFr.96.20 CHF +0.40
Zoetis Inc $46.46 USD +0.345
View Industry Companies
 

Industry Analysis

ICCC

Industry Average

Valuation ICCC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUCELL CORP, please visit www.immucell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.